Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HAU8
UPID:
RNPL1_HUMAN
Alternative names:
Arginyl aminopeptidase-like 1; Methionyl aminopeptidase
Alternative UPACC:
Q9HAU8; Q5XKC3; Q6NX56; Q96AC9; Q9H033; Q9NVD0
Background:
Aminopeptidase RNPEPL1, also known as Arginyl aminopeptidase-like 1 and Methionyl aminopeptidase, exhibits broad specificity in hydrolyzing N-terminal amino acids such as methionine, citrulline, or glutamine. This enzyme plays a crucial role in protein processing, influencing protein maturation and function.
Therapeutic significance:
Understanding the role of Aminopeptidase RNPEPL1 could open doors to potential therapeutic strategies. Its involvement in protein processing suggests its potential impact on various biological pathways and diseases.